Single Cycle of Arsenic Trioxide–Based Consolidation Chemotherapy Spares Anthracycline Exposure in the Primary Management of Acute Promyelocytic Leukemia

PURPOSE: Event-free survival following all-trans-retinoic acid (ATRA) –based therapy for acute promyelocytic leukemia (APL) averages 70% at 5 years. While arsenic trioxide (ATO) can induce remissions in 95% of relapsed patients, few studies have addressed the integration of ATO into the primary mana...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Gore, Steven D., Gojo, Ivana, Sekeres, Mikkael A., Morris, Lawrence, Devetten, Marcel, Jamieson, Katarzyna, Redner, Robert L., Arceci, Robert, Owoeye, Ibitayo, Dauses, Tianna, Schachter-Tokarz, Esther, Gallagher, Robert E.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Society of Clinical Oncology 2010
Gaiak:
Original Reports
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC2834430/
https://ncbi.nlm.nih.gov/pubmed/20085935
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2009.25.5158
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak